The U.S. Food and Drug Administration on Wednesday approved an injection for "double chin" reduction, developed by the Kythera Biopharmaceuticals.
The drug, Kybella, is a formulation of synthetically derived deoxycholic acid, which destroys fat under the chin, leaving surrounding tissue largely unaffected.